Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Maternity
  4. Back
  5. Medical conditions in pregnancy
  6. Thrombocytopenia in Pregnancy (453)
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Thrombocytopenia in Pregnancy (453)

Warning

Please report any inaccuracies or issues with this guideline using our online form

Definition

The normal serum level of platelets in pregnancy is 120–400 x 109/l. 

Reduction of serum platelet count is considered; 

Mild   >100-120 x 109/l
Moderate50–100 x 109/l
Severe <50 x 109/l  

Symptoms

Common symptoms of thrombocytopenia include petechiae, epistaxis and more rarely, haematuria and gastrointestinal bleeding. Symptoms are uncommon above a count of 50 x 109/l  

Causes

  • Spurious result
  • Gestational thrombocytopenia
  • Immune thrombocytopenia (ITP)
  • Pre- eclampsia and HELLP (Haemolysis, Elevated LFTs, Low Platelets) syndrome
  • Disseminated Intravascular Coagulation (DIC)
  • Haemolytic Uraemic Syndrome (HUS)
  • Thrombotic Thrombocytopenic Purpura (TTP)
  • HIV, Hep C and other infections
  • Drugs
  • Systemic Lupus Erythematosus (SLE)
  • Antiphospholipid syndrome (ALPS)
  • Bone marrow disease e.g. congenital platelet disorder, leukaemia, lymphoma

Incidence

  • 8-10% pregnant women at term have thrombocytopenia
  • 75% of these have gestational thrombocytopenia
    • No clinical implications
    • Normal platelet count out with pregnancy
    • Late onset, usually third trimester
    • Count < 70 is unusual
    • Platelet count returns to normal within 2-12 weeks postpartum
  • 21% cases due to pre-eclampsia, associated with;
    • Raised BP, proteinuria
    • Deranged LFTs, U&Es, haemolysis
  • 4% cases due to Immune Thrombocytopenia
    • 2/3 ITP cases already known
    • Can have significant thrombocytopenia in first trimester
    • Diagnosis of exclusion
  • Miscellaneous causes in the remaining 1% cases e.g. HUS, TTP etc

Evaluation of thrombocytopenia in pregnancy

Exclude medical disorders and drug induced thrombocytopenia

  • Blood Film (mandatory)
    • Platelet clumping – repeat in citrate / lithium heparin
    • Microangiopathic haemolytic anaemia – HELLP/TTP/HUS/DIC
  • LFTs, U&Es, Urates, coagulation screen, HIV, Hep C
  • If all negative, the diagnosis of exclusion is either gestational thrombocytopenia or ITP

Management

  • Isolated mild thrombocytopaenia (120-150) confirmed – no additional monitoring required
  • Isolated moderate/severe thrombocytopenia confirmed – monitor platelet count
    • Monthly in 1st and 2nd trimester
    • Fortnightly in 3rd trimester
    • Weekly from 36 weeks

Note: Frequency of monitoring depends on severity 

  • Platelet count should be checked on admission to the labour ward
  • Platelet antibody testing is unhelpful and does not predict fetal / neonatal thrombocytopenia
  • Bone marrow aspirate is not required (unless haematological malignancy suspected)
  • Liaise with anaesthetist when platelet count <100x109/l
  • Liaise with haematologist when platelet count <70x109/l
  • Treat when platelet count is below the intervention level
  • If there is development of significant bleeding symptoms, a target platelet count of >50x109/l should be aimed for

Intervention levels for non-haemorrhagic thrombocytopenia

Intervention

Platelet count(x109/l)

Antenatal, no invasive procedures planned

Vaginal delivery

Operative or instrumental delivery

Epidural anaesthesia

<20

<40

<50

<100

The remainder of this guideline refers to the management of cases of ITP in pregnancy. Other causes of thrombocytopenia should be managed according to their underlying pathology.

Management of ITP     

Maternal considerations

Most women only require treatment for delivery. Usually either oral corticosteroids or IV immunoglobulins are used

  • Oral Corticosteroids
    • Response in 2-3 weeks
    • Use lowest effective dose for shortest time
    • Start with 20mg/day of prednisolone until a response is obtained. Assess response on a weekly basis.
    • Increase dose to 1mg/kg/day if no or minimal response at one week
    • Following an initial response, wean the dose to the lowest that maintains a platelet count above intervention level
    • Disadvantages – glucose intolerance, hypertension, psychosis, osteoporosis
  • IV gamma globulin
    • Response in 24-48 hrs (lasts 2-3 weeks)
    • Dosage: 0.4g/kg/day for 5 days or 1g/kg for 2 days, repeated after 48 hrs if there is no response
    • Disadvantages - slow infusion, plasma product, allergic reactions, headache, less commonly aseptic meningitis, rarely renal toxicity
  • Platelet transfusions are given as a last resort for bleeding or prior to surgery along with IVIG and tranexamic acid
  • IV anti D has lost its license for treatment of ITP
  • Intravenous methylprednisolone may be considered in patients who fail to respond to oral prednisolone and/or immunoglobulins
  • Rituximab and azathioprine are effective but should only be considered in resistant cases
  • Splenectomy should be avoided in pregnancy but may become necessary in extreme cases. If so, it should be performed in the 2nd trimester. Penicillin prophylaxis should be continued post splenectomy and vaccinations should be given post partum

Fetal Considerations

Babies born to mothers suffering from ITP may have a low platelet count. Maternal platelet count co-relates poorly with neonatal platelet count.

Predictors for neonatal thrombocytopenia are

  • Previously affected sibling (Neonatal alloimmune thrombocytopenia {NAIT} should be considered in these cases, maternal platelet count is usually normal in NAIT)
  • Previous splenectomy
  • Severe ITP

5% of babies have a platelet count between 20-50 x 109/l

5% have a platelet count <20 x 109/l 

Intracranial haemorrhage is rare (<1% cases)

Fetal scalp electrode, fetal blood sampling, ventouse and complicated forceps delivery should be avoided

Caesarean section is reserved for obstetric indications only

Assessment of the newborn

  • All babies should have a cord blood sample taken
    • Normal FBC – no further samples required
    • Below normal FBC – neonatal FBC sample must be taken
    • Below normal neonatal sample – alternate day FBC for one week as nadir usually occurs at day 3-5 of life
  • Treatment
    • Platelets >20 x 109/l – Monitor. Oral vitamin K if <50 x 109/l
    • Platelets <20 x 109/l – IVIG + cranial USS + oral vitamin K (and consider NAIT as an alternative diagnosis)
    • Life threatening bleeding – IVIG + platelet transfusion (consider transfusion of HPA 1a 5b negative platelets until NAIT is excluded)
  • Thrombocytopenia may take from a few weeks to occasionally months to resolve

Editorial Information

Last reviewed: 28/05/2016

Next review date: 30/06/2021

Author(s): Catherine Bagot.

Version: 2

Approved By: Obstetrics Clinical Governance Group

Document Id: 453

References

Catherine Nelson-Piercy. Thrombocytopenia, Haematological problems, Handbook of obstetric medicine, third edition.

Provan D. et al., International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-186

Myers B. Thrombocytopenia in pregnancy. The Obstetrician & Gynaecologist 2009;11:177– 183.